FindTrial
Sign In

TransCon IL-2 β/γ

DRUG2 trials

Sponsors

Ascendis Pharma Oncology Division A/S, Ascendis Pharma A/S

Conditions

2L+ Cervical CancerAdvanced Solid TumorHead and Neck NeoplasmsLocally Advanced Solid TumorMetastatic Solid TumorNeoadjuvant MelanomaNeoadjuvant Non-Small Cell Lung CancerPlatinum-resistant Ovarian Cancer

Phase 1

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Active, not recruitingNCT05081609
Ascendis Pharma Oncology Division A/S2L+ Cervical Cancer, Advanced Solid Tumor, Locally Advanced Solid Tumor +10
Start: 2022-01-11End: 2029-08-01Updated: 2026-02-24

Phase 2

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
TerminatedNCT05980598
Ascendis Pharma A/SHead and Neck Neoplasms
Start: 2023-09-29End: 2025-03-28Updated: 2025-08-01

Related Papers

TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.
Journal of Clinical Oncology2024-06-011 citations
Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.
Journal of Clinical Oncology2023-06-01
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
Journal for ImmunoTherapy of Cancer2022-07-0134 citations
IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors.
Journal of Clinical Oncology2022-06-01
TransCon IL-2 β/γ, a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 analog, demonstrates improved pharmacokinetics and profound expansion of cytotoxic immune cells in non-human primates.
Journal of Clinical Oncology2022-06-01